Perspective · 3 Nov 2025
Case reportPublished 2015
Langerhans Cell Sarcoma: Treatment with Dose-adjusted EPOCH
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Langerhans cell sarcoma (LCS) is a rare malignancy with no specific defined treatment strategy.Chemotherapy is the preferred option in cases with systemic involvement, though no consensus exists on thepreferred regimen. Case: A sixty-six year old male presented with advanced-stage LCS involving the bone marrow (BM) and spleen. Immunohistochemical analysis of the BM-sample confirmed the diagnosis of LCS. The patient was treated withchemotherapy utilizing dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide and Doxorubicin (DAEPOCH). The patient achieved complete remission and was able to tolerate the entire course (6 cycles) of chemotherapy with continued response at 10 months. Conclusion: Due to the rarity of the disease no standard treatment modality exists; most successful treatment options described are anecdotal reports. Due to the paucity of such data and inability to include enough patients on clinical trials, various combination chemotherapy options have been used for best clinical response. The unattractive response rate to CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in previously described case series and the benefit of Etoposide in treating Langerhans cell histiocytosis and primitive sarcoma regimens along with an acceptable adverse effect profile, had us chose DA-EPOCH for our patient. We demonstrate that DAEPOCH is a tolerable and an efficacious treatment regimen for LCS.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Chemotherapy: Open Access.
Opinion · 3 Nov 2025
Evaluation of Surgical Radiotherapy and Chemotherapy in the Treatment of Gynaecological Malignancies
Research article · 18 Aug 2025
Response Evaluation to Oxaliplatin-Based Adjuvant Chemotherapy after Curative Resection between Right and Left-Sided Stage II and III Colon Cancer: A Retrospective Survival Analysis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalChemotherapy: Open Access
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Abhisek Swaika”
- BylineArticles whose byline prints “Neha Sood”
- BylineArticles whose byline prints “David M Menke”
- BylineArticles whose byline prints “Asit K Jha”
- BylineArticles whose byline prints “Sikander Ailawadhi”

